Log In
BCIQ
Print this Print this
 

Anyara, naptumomab estafenatox (ABR-217620)

Also known as: TTS CD3

  Manage Alerts
Collapse Summary General Information
Company Active Biotech AB
Description5T4 antibody combined with a mutated staphylococcal enterotoxin A (SEA)
Molecular Target Oncofetal antigen 5T4
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer
Regulatory Designation
PartnerNeoTX Therapeutics Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$71.0M

$0.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/26/2016

$71.0M

$0.3M

Undisclosed

Get a free BioCentury trial today